

2013 Pediatric Influenza Bulletin

Highlights for this year:

- Annual influenza vaccination of all persons aged 6 months and older continues to be recommended.
- 2013-14 U.S. trivalent influenza vaccines will contain an A/California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus. Quadrivalent vaccines will include an additional vaccine virus, a B/Brisbane/60/2008-like virus.
- Several new, recently-licensed vaccines are available for the 2013-14 season, and are acceptable alternatives to other licensed vaccines indicated for their respective age groups when otherwise appropriate. Within approved indications and recommendations, the Centers for Disease Control and Prevention (CDC) states no preferential recommendation for any type or brand of licensed influenza vaccine over another.
- The former abbreviation TIV (Trivalent Inactivated Influenza Vaccine, previously used for inactivated influenza vaccines) has been replaced with the new vaccine category abbreviation IIV (Inactivated Influenza Vaccine), which includes quadrivalent inactivated influenza vaccines (IIV4), and trivalent formulations (IIV3), both available in 2013-14 and indicated for persons aged 6 months and older
- LAIV refers to live-attenuated influenza vaccine, available only as a quadrivalent formulation for 2013-14, and indicated for healthy, non-pregnant persons aged 2 through 49 years
- Additionally, a trivalent cell culture-based inactivated influenza vaccine (ccIIV3), a recombinant hemagglutinin (HA) vaccine (RIV3), a high dose formulation (IIV3), and an intradermal formulation (IIV3) are licensed this year. <http://www.cdc.gov/flu/professionals/vaccination/index.htm>

Influenza vaccines for pediatric use supplied by the VT Immunization Program in the 2013-14 season

Manufacturer	Vaccine/ndc	Formulation	Thimerosal preservative	Age availability
Sanofi	Fluzone 49281-0392-15	Multi-dose 5mL vial (IIV3)	Yes	6 months - 18 years
	Fluzone 49281-0113-25	Single dose pre-filled 0.25mL syringe (IIV 3)	No	6-35 months
GlaxoSmithKline	Fluarix 58160-0900-52	Single dose pre-filled 0.5mL syringe (IIV 4)	No	3 years -18 years
MedImmune	FluMist 66019-0300-10	0.2mL prefilled intranasal sprayer (LAIV4)	No	2 years-18 years

Influenza Vaccine Dosing for Inactivated Influenza Vaccine

Age	Dose	Number of doses
6—35 months	0.25 mL	1 or 2
3—8 years	0.5 mL	1 or 2
9 years to adult	0.5 mL	1


VACCINE INFORMATION STATEMENTS

<http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.pdf>

<http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.pdf>

Many Vaccine Information Statements are available in Spanish and other languages. See <http://www.immunize.org/vis/>

Influenza vaccine dosing algorithm for children aged 6 months though 8 years—receiving influenza vaccine for the first time - Advisory Committee on Immunization Practices 2013-14 season



* Doses should be administered at least 4 weeks apart.

Concurrent Administration of Influenza Vaccine With Other Vaccines

- Inactivated vaccines do not interfere with the immune response to other inactivated vaccines or to live vaccines.
- Inactivated or live vaccines can be administered simultaneously with LAIV.
- However, after administration of a live vaccine, at least 4 weeks should pass before another live vaccine is administered.

Administration of FluMist

- FluMist recipients can breathe normally during administration. Sniffing is not necessary
- Dripping, sneezing, or swallowing may occur after vaccination. Re-vaccination is not necessary

Questions? Call us toll-free at (800) 640-4374 or email us at immunizationprogram@state.vt.us